title: Exceptional Duration of Radium-223 in Prostate Cancer With a BRCA2 Mutation.
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
authors.forename: Allie E
authors.initials: AE
authors.lastname: Steinberger
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
authors.forename: Patrick
authors.initials: P
authors.lastname: Cotogno
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
authors.forename: Elisa M
authors.initials: EM
authors.lastname: Ledet
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA.
authors.forename: Brian
authors.initials: B
authors.lastname: Lewis
authors.affiliation: Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA; Department of Medicine and Urology, Tulane Cancer Center, Tulane University School of Medicine, New Orleans, LA. Electronic address: osartor@tulane.edu.
authors.forename: Oliver
authors.initials: O
authors.lastname: Sartor
mesh_terms: D024682:BRCA2 Protein / Q000235:genetics*; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000556:secondary; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000235:genetics; D019275:Radiopharmaceuticals / Q000008:administration & dosage* / Q000627:therapeutic use; D011883:Radium / Q000008:administration & dosage* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D024682:BRCA2 Protein; C551750:BRCA2 protein, human; D019275:Radiopharmaceuticals; C000615150:Radium-223; D011883:Radium
keywords: BRCA2; Mutation; Prostate cancer; Radium-223; mCRPC